88321-07-7

Basic information

• Product Name: N-(2-propylpentanoyl)glycine
• CAS NO: 88321-07-7
• Molecular Formula: C₁₀H₁₉NO₃
• Molecular Weight: 201.2628
• Mol File: 88321-07-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 396.4°C at 760 mmHg
• Flash Point: 193.5°C
• Density: 1.034g/cm³
• Vapor Pressure: 2.17E-07mmHg at 25°C
• Refractive Index: 1.462
• CAS DataBase Reference: N-(2-propylpentanoyl)glycine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-propylpentanoyl)glycine(88321-07-7)
• EPA Substance Registry System: N-(2-propylpentanoyl)glycine(88321-07-7)

Safety Data

• Hazardous Substances Data: 88321-07-7(Hazardous Substances Data)

Upstream product

• 2936-08-5 valproyl chloride 
• 56-40-6 glycine 
• 99-66-1 valproic acid 

Relevant articles and documents

Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine

Purpose. To explore the possibility of utilizing valproyl derivatives of GABA and glycine as new antiepileptics by using the structure pharmacokinetic-pharmacodynamic relationship (SPPR) approach. Methods. The pharmacokinetics and pharmacodynamics (anticonvulsant activity and neurotoxicity) of the following four conjugation products of valproic acid (VPA), glycine and GABA were investigated: valproyl glycine, valproyl glycinamide, valproyl GABA and valproyl gabamide. Results. Only valproyl glycinamide showed a good anticonvulsant profile in both mice and rats due to its better pharmacokinetic profile. Valproyl glycinamide was more potent than one of the major antiepileptic agents - VPA and showed a better margin between activity and neurotoxicity. Valproyl glycine and valproyl GABA were partially excreted unchanged in the urine (fe is 50% and 34%, respectively), while the urinary metabolites of the amide derivatives were valproyl glycine and valproyl GABA. Conclusions. The four investigated valproyl derivatives did not operate as chemical drug delivery systems (CDDS) of glycine or GABA, but acted rather as drugs on their own. The current study demonstrates the benefit of the SPPR approach in developing and selecting a potent antiepileptic compound in intact animals based not only on its intrinsic pharmacodynamic activity, but also on its better pharmacokinetic profile.

5-fluorouracil, 2'-deoxy-5-fluorouridine and 1-carbomoyl-5-fluorouracil compounds

A 5-fluorouracil derivative represented by the formula (1): STR1 wherein A represents a group represented by STR2 wherein R1 represents a hydrogen atom or OR5 group, R2, R3 and R5 may be the same or different and each represents a hydrogen atom or a group represented by the following formula (2): STR3 wherein R6 represents an acyl group, R7 represents a hydrogen atom, a straight or branched alkyl group, a cycloalkyl group, an aralkyl group, a lower alkenyl group or a phenyl group, and n is an integer of 0 to 6, provided that at least one of R2, R3 and R5 is a group represented by the formula (2), and the case wherein R2 and R5 are both hydrogen atoms is excluded, R4 represents a group represented by the formula (2), and X represents an alkylene group or a cycloalkylene group, and an antitumor agent containing the same as an active ingredient.